Navigation Links
Par Pharmaceutical Begins Shipment of Generic Zegerid®
Date:7/1/2010

WOODCLIFF LAKE, N.J., July 1 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it began shipping the 20mg/1100mg and 40mg/1100mg strengths of omeprazole and sodium bicarbonate capsules to the trade. Omeprazole and sodium bicarbonate capsules are the generic version of Santarus’ Zegerid®. Annual U.S. sales of Zegerid capsules are approximately $195 million, according to IMS Health data. Par has been awarded 180 days of marketing exclusivity for being the first to file an ANDA containing a paragraph IV certification for these strengths of the product.

On April 14, 2010, the District Court of Delaware held that the patents covering Zegerid are invalid. The case is currently on appeal at the Court of Appeals for the Federal Circuit.

Important information about omeprazole and sodium bicarbonate capsules

Omeprazole and sodium bicarbonate is a combination of omeprazole, a proton-pump inhibitor, and sodium bicarbonate, an antacid.  

Omeprazole and sodium bicarbonate is indicated for the short-term treatment of duodenal ulcer, the short-term treatment (4-8 weeks) of active benign gastric ulcer, the treatment of heartburn and other symptoms associated with Gastroesophageal Reflux Disease (GERD) and short-term treatment (4-8 weeks) of erosive esophagitis which has been diagnosed by endoscopy.

About Par Pharmaceutical Companies, Inc.

Par Pharmaceutical Companies, Inc. is a U.S.-based specialty pharmaceutical company. Through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, it develops, manufactures and markets higher-barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals. For press releases and other company information, visit www.parpharm.com.

Safe Harbor Statement

Certain statements in this news release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K in other of the Company’s filings with the SEC from time to time, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and on general industry and economic conditions. Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.


'/>"/>
SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals Adds Former U.S. Surgeon General, Steven Galson, to its Board of Directors
2. Endo Pharmaceuticals Completes Next Step in Regulatory Process for FORTESTA™ for Men With Low Testosterone
3. Simcere Pharmaceutical Group Files Annual Report on Form 20-F
4. Renhuang to Launch New Bio-pharmaceutical Product - Ginseng and Deer Antler Extract
5. NeoStem Pharmaceutical Subsidiary Announces Two cGMP Lines are Now Fully Operational in New Facility
6. Hospira Announces Intention to Complete Tender Offer for Shares of Javelin Pharmaceuticals
7. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT
8. Frankfurt To Host Worlds Largest Pharmaceutical Services Events In 2011
9. Oramed Pharmaceuticals to Present at the 70th Scientific Sessions of the American Diabetes Association
10. Global Pharmaceutical R&D Productivity Declining According to Thomson Reuters, CMR International
11. Jazz Pharmaceuticals JZP-6 to be Reviewed at a Joint Meeting of the FDAs Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee on August 20, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/12/2017)... Kineta, Inc., a biotechnology company focused on the development of ... R&D and Head of Virology Kristin Bedard has been invited ... and Beyond meeting sponsored by Life Science Washington.  This ... AM PDT at the Agora Conference Center in ... be joined by other leaders in infectious disease research and ...
(Date:6/9/2017)... , June 9, 2017 More than ... further effort to help spread lessons learned from clinical ... International Diabetes Federation (IDF) and Eli Lilly and Company ... the second phase of the Bringing Research in Diabetes ... their commitment to helping people with diabetes effectively manage ...
(Date:6/7/2017)... , June 7, 2017 Endo International ... June 7, 2017, the Hon. Joseph R. Goodwin ... of West Virginia , entered a ... Inc. Pelvic Repair System Products Liability Litigation (the "MDL") ... MDL cases to provide expert disclosures on specific causation ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... Continually at the forefront of ... Drops™ have received the Non-GMO Project Verified seal. All five flavors of the ... only third-party verification for non-GMO foods and products in North America. , Available ...
(Date:6/28/2017)... Pekin, IL (PRWEB) , ... June 28, 2017 , ... ... research shows that every 62 minutes, at least one person dies as a direct ... grows, a greater need exists for qualified treatment providers. The iaedp Foundation meets this ...
(Date:6/28/2017)... ... June 28, 2017 , ... Canadian Zeolite Corp. (the “Company”) ... year study conducted by the University of Saskatchewan in partnership with PotashCorp, Agrium ... brine-impacted groundwater. As a part of the study, batch adsorption experiments were conducted ...
(Date:6/27/2017)... Fla. (PRWEB) , ... June 27, 2017 , ... ... today announced the appointment of Mike Finnegan to the position of Executive Vice ... years of experience in healthcare technology, telehealth and medical device sales leadership. He ...
(Date:6/27/2017)... ... 27, 2017 , ... The Congressional Budget Office (CBO) projects that the Better ... Patient Protection and Affordable Care Act (ACA), would result in 22 million Americans losing ... law. , More than 20 million Americans have gained health insurance under the ACA, ...
Breaking Medicine News(10 mins):